NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has focused their efforts on developing innovative product candidates that target the treatment or prevention of a broad array of infections in hospital and community environments. Because of the rapid increase in infectious microbes that are resistant to current drugs, many of these infections have become increasingly difficult to treat. Vitro and in vivo tests have proven that the company’s compounds kill a broad range of bacteria, viruses and other infection causing microbes, even those that are resistant to multiple antibiotics. For further information, visit the Company’s web site at www.novabaypharma.com.
- 18 years ago
QualityStocks
NovaBay Pharmaceuticals, Inc. (AMEX: NBY)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Hallmark Venture Group, Inc. (OTC: HLLK) Completes Drone Technology Acquisition, Transitions to Operating Business
Hallmark Venture Group (OTC: HLLK) announced the completion of a strategic transaction that transforms the company from…
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on DNA Repair Cancer Therapies
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced…
-
QualityStocksNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Releases RoadSight UGV Demonstration Video
Safe Pro Group (NASDAQ: SPAI), has released a demonstration video highlighting its new RoadSight capability,…